# US 2019/0167582 A1 · Methotrexate Composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167582 A1
- Document ID: US20190167582A1
- Status: Published application
- Kind: A1
- Application number: 16/266,305
- Filed: 2019-02-04
- Published: 2019-06-06
- Earliest claimed: 2012-01-06
- Assignees: Rosemont Pharmaceuticals Ltd
- Applicants: Rosemont Pharmaceuticals Ltd.
- Inventors: Carl Tierney; Stacey Powell; Peter Braybrooke; Geraint Jones
- Web page: https://patentgrep.com/patent/US20190167582A1

## CPC

- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

## Claims

### Claim 1

A Methotrexate composition for oral administration, said composition comprising a pharmaceutically acceptable salt of Methotrexate, a citrate buffer system, a preserving agent, and purified water, wherein the pH of the composition is 6 to 7.

### Claim 2 (depends on 1)

The Methotrexate composition according to claim 1 wherein the pharmaceutically acceptable salt of Methotrexate used is Methotrexate disodium.

### Claim 3 (depends on 1)

The Methotrexate composition according to claim 1 wherein the pH of the composition is in the range of pH 6.1-6.5.

### Claim 4 (depends on 1)

The Methotrexate composition according to claim 1 wherein the pH of the composition is in the range of pH 6.25+/−0.15.

### Claim 5 (depends on 1)

The Methotrexate composition according to claim 1 wherein the citrate buffer system comprises Citric Acid and Sodium Citrate.

### Claim 6 (depends on 1)

The Methotrexate composition according to claim 1 wherein the citrate buffer system has a strength between 2 to 200 millimolar, and optionally between 2 to 20 millimolar.

### Claim 7 (depends on 1)

The Methotrexate composition according to claim 1 wherein the preserving agent comprises any or any combination of Sodium Methyl Hydroxybenzoate, Sodium Ethyl Hydroxybenzoate, Sodium Propyl Hydroxybenzoate, Sodium Benzoate or Potassium Sorbate.

### Claim 8 (depends on 1)

The Methotrexate composition according to claim 1 wherein the preserving agent comprises Sodium Methyl Hydroxybenzoate and/or Sodium Propyl Hydroxybenzoate.

### Claim 9 (depends on 1)

The Methotrexate composition according to claim 1 wherein the composition further comprises a flavouring compound or sweetening agent.

### Claim 10 (depends on 9)

The Methotrexate composition according to claim 9 wherein the flavouring compound or sweetening agent comprises Sucralose, Acesulfame K, any other water soluble sweetener or Raspberry Flavour 545742E.

### Claim 11 (depends on 9)

The Methotrexate composition according to claim 9 wherein the flavouring compound or sweetening agent comprises Sucralose.

### Claim 12 (depends on 1)

The Methotrexate composition according to claim 1 wherein the pharmaceutically acceptable dosage of the Methotrexate salt used is 2.5 mg/5 ml, 5 mg/5 ml, 10 mg/5 ml or in the range of 0.05 mg/1 ml to 20 mg/1 ml.

### Claim 13 (depends on 1)

The Methotrexate composition according to claim 1 wherein the pharmaceutically acceptable dosage of the Methotrexate salt used is equivalent to 2.5 mg/1 ml methotrexate base.

### Claim 14

A Methotrexate composition for oral administration, said composition comprising a pharmaceutically acceptable salt of Methotrexate, a citrate buffer system, Sodium Methyl Hydroxybenzoate, Sodium Propyl Hydroxybenzoate, Sucralose, and purified water, wherein the pH of the composition is 6 to 7.

### Claim 15 (depends on 14)

The Methotrexate composition according to claim 14 wherein the pH of the composition is in the range of pH 6.1-6.5.

### Claim 16 (depends on 14)

The Methotrexate composition according to claim 14 wherein the pH of the composition is in the range of pH 6.25+/−0.15.

### Claim 17 (depends on 14)

The Methotrexate composition according to claim 14 wherein the citrate buffer system comprises Citric Acid and Sodium Citrate.

### Claim 18 (depends on 14)

The Methotrexate composition according to claim 14 wherein the citrate buffer system has a strength between 2 to 200 millimolar, and optionally between 2 to 20 millimolar.

### Claim 19 (depends on 14)

The Methotrexate composition according to claim 14 wherein the pharmaceutically acceptable dosage of the Methotrexate salt used is 2.5 mg/5 ml, 5 mg/5 ml, 10 mg/5 ml or in the range of 0.05 mg/1 ml to 20 mg/1 ml.

### Claim 20 (depends on 14)

The Methotrexate composition according to claim 14 wherein the pharmaceutically acceptable dosage of the Methotrexate salt used is equivalent to 2.5 mg/1 ml methotrexate base.
